HB170 Alabama 2017 Session

Under existing law, the Alabama State Board of Pharmacy is responsible for regulating the practice of pharmacy and the management and operation of pharmacies in the state

This bill would rename drug inspectors employed by the board as drug investigators

This bill would clarify that a pharmacist is a health care provider

This bill would specify the qualifications a laboratory must satisfy for the board to use its product analysis data

This bill would increase the maximum fee the board may charge for certain new pharmacy permit, permit renewal, and permit transfer applications and would specify fee ranges the board may charge for certain out-of-state pharmacy permit and permit renewal applications

This bill would increase the frequency of registration for certain drug supply chain entities from biennially to annually, would add packagers, third party logistic providers, private label distributors, and other pharmacy businesses identified in the supply chain to those entities required to register, and would increase the fee range for a permit due to transfer of ownership

This bill would prohibit any entity identified within a drug supply chain from shipping a legend drug or device into the state without a valid permit issued by the board and would provide a civil penalty for each violation

This bill would require each holder of a permit to ship a legend drug or device into the state, upon request of the board, to provide a list of all trading partners

This bill would authorize the board to discipline any pharmacist who obtains registration from the board by fraudulent means

This bill would provide further for the initial and renewal registration process and fees for pharmacy technicians and continuing education requirements

This bill would prohibit a prescriber from reselling a compound drug product administered in his or her office and would clarify that the board recognizes and enforces the provisions of the United States Pharmacopoeia or National Formulary relating to drug handling or compounding processes

This bill would also authorize the board to permit any manufacturer, manufacturer affiliate, bottler, packager, repackager, third party logistic provider, wholesale drug distributor, private label distributor, or pharmacy business identified in the supply chain of any drugs, legend drugs, medicines, chemicals, or poisons for medicinal purposes and would clarify adherence to requirements established by the FDA Guidelines in the Drug Quality and Security Act

Relating to the Alabama State Board of Pharmacy; to amend Sections 20-2-90, 20-2-190, 34-23-1, 34-23-3, 34-23-9, 34-23-30, 34-23-32, 34-23-32.1, 34-23-33, 34-23-70, 34-23-92, 34-23-131, 34-23-159, 34-23-160, and 34-23-162, Code of Alabama 1975, to rename board drug inspectors as drug investigators; to clarify the status of a pharmacist as a health care provider; to list the qualifications a laboratory must satisfy for the board to use its product analysis data; to increase the maximum fee for certain new pharmacy permit, permit renewal, and permit transfer applications; to specify fee ranges the board may charge for certain out-of-state pharmacy permit and permit renewal applications; to increase the frequency of registration for certain drug supply chain entities from biennially to annually; to require packagers, third party logistic providers, private label distributors, and other pharmacy businesses identified in the drug supply chain to register annually; to increase the fee range for a permit due to transfer of ownership; to prohibit any entity identified within a drug supply chain from shipping a legend drug or device into the state without a valid permit and to provide a civil penalty for each violation; to require each holder of a permit to ship a legend drug or device into the state, upon request of the board, to provide a list of all trading partners; to authorize the board to discipline any pharmacist who obtains registration from the board by fraudulent means; to provide further for the initial and renewal registration and continuing education requirements of pharmacy technicians; to prohibit a prescriber from reselling a compound drug product administered in his or her office; to require the board to recognize and enforce drug handling and compounding processes of the United States Pharmacopoeia or National Formulary; to add Section 34-23-32.2 to the Code of Alabama 1975, to authorize the board to permit any manufacturer, manufacturer affiliate, bottler, packager, repackager, third party logistic provider, wholesale drug distributor, private label distributor, or pharmacy business identified in the supply chain of any drugs, legend drugs, medicines, chemicals, or poisons for medicinal purposes and to clarify adherence to requirements established by the FDA Guidelines in the Drug Quality and Security Act; and to repeal Sections 34-23-152, 34-23-153, 34-23-154, 34-23-155, 34-23-156, and 34-23-157, Code of Alabama 1975, relating to compounding of drugs.